Head-to-head verdict
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, no pay-to-win placement.
One of the rare programs offering an oral/sublingual route on both molecules with all-inclusive pricing — but the verdict marks it down hard because the numbers are company-stated, not independently verified.
Visit Direct MedsThe most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxCoreAge Rx takes it with a higher Verdict Score — 94/100 to 82/100 (grade A vs B−). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Direct Meds still earns its place — needle-averse patients who specifically want a sublingual GLP-1 option and are willing to vet a newer operator themselves.
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
| Metric | Direct Meds | CoreAge Rx |
|---|---|---|
| Verdict Score | 82/100 | 94/100 |
| Grade | B− | A |
| Semaglutide | $179/mo | $149/mo |
| Tirzepatide | $224/mo | $349/mo |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | No |
What we like
The caveats
What we like
The caveats
Also worth a look
Needle-averse patients who specifically want a sublingual GLP-1 option and are willing to vet a newer operator themselves.
Visit Direct Meds Read the full Direct Meds review →Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.